Vol.

No.

March 01, 2024Mar 01, 2024

DOWNLOAD THE PDF

Multi-target FIT aims to offer inexpensive, high-sensitivity alternative to FIT in colorectal cancer screening

Cover Story

Clinical

Multi-target FIT aims to offer inexpensive, high-sensitivity alternative to FIT in colorectal cancer screening

By Matthew Bin Han Ong

Developers of an investigational multi-target screening test for colorectal cancer and its precursors are aiming to replace the widely used conventional fecal immunochemical test.

Health Equity

Large study of U.S. veterans shows that gaining housing is associated with improved cancer outcomes

By Jacquelyn Cobb

Clinical Trials & Tribulations

Cancer AI systems: We need oncologists to help us build trusted models

By Bernard Chien

Black History Month Free In the Archives

Before her legendary career at NIH, Vivian Pinn was the second Black woman to graduate from UVA med school
As a student, the first director of the NIH Office of Research on Women’s Health helped desegregate Charlottesville

By Robert A. Winn and Alexandria Carolan

In Brief

AACR announces 2024 scientific achievement awards

ARPA-H commits $100M to accelerate women’s health research

President’s Cancer Panel recommends five priority areas for the National Cancer Plan

Young, Rader, Sanchez-Johnsen, Marassi named to leadership roles at Medical College of Wisconsin Cancer Center

Covens named chair, Tsien named vice chair of NRG Oncology Canadian Members Subcommittee

City of Hope establishes mobile cancer prevention and screening program

Clinical Roundup

Study: Many don’t know alcohol, lack of exercise, high fat/processed foods are risk factors for colorectal cancer

Drugs & Targets

FDA issues final decision to withdraw approval of Pepaxto

FDA, industry actions end sales of PFAS in U.S. food packaging

FDA grants Epkinly priority review sBLA for difficult-to-treat R/R follicular lymphoma

FDA accepts BLA for Tevimbra for 1L treatment of G/GEJ cancers

Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI

Exact Sciences launches Riskguard hereditary cancer test in the U.S.

NCI Trials

NCI Trials for March 2024

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE